North Carolina is currently home to 2641 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Durham, Charlotte, Winston-Salem and Chapel Hill. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study of Single Doses of SBT777101 in Subjects With Hidradenitis Suppurativa
NCT06361836
Recruiting
This study will test the safety and effects of SBT777101 when given as a single dose to subjects with hidradenitis suppurativa. Increasing dose levels will be given after the safety at lower dose levels is shown.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/24/2025
Locations: Duke University, Durham, North Carolina
Conditions: Hidradenitis Suppurativa
Register for Updates
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
NCT06014658
Recruiting
This is a first-in-human (FIH), open label Phase 1/1b / Phase 2 study in patients with advanced metastatic solid tumors refractory to standard treatment. Phase 1 will identify potential optimal biologically relevant doses (OBRD) and the maximum tolerated dose (MTD) of MBRC-101 at one 1 or more dosing regimens. Phase 1b will evaluate the safety and preliminary clinical activity of MBRC-101 at potential OBRDs. Phase 1 and Phase 1b will both characterize single and multiple-dose PK profiles and eva... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: Carolina BioOncology Institute, Huntersville, North Carolina
Conditions: Cancer
Register for Updates
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
NCT05828511
Recruiting
This study is researching an experimental drug called linvoseltamab (called "study drug"). The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are eligible for high dose chemotherapy with autologous stem cell transplantation (transplant-eligible) or ineligible for autologous stem cell transplantation (transplant-ineligible). The aim of this clinical trial is to study the safety, tolerability (how the body reacts to the drug), and effectiveness (tumor shrinkage)... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: Levine Cancer Institute, Charlotte, North Carolina
Conditions: Multiple Myeloma
Register for Updates
Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT05168566
Recruiting
This is a Phase 2b, multicenter, open-label study to evaluate the safety and efficacy of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Non-resistant Uncommon EGFR Mutations Only, Including L861Q, G719X, and/or S768I)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: FirstHealth Cancer Center, Pinehurst, North Carolina
Conditions: Non-small Cell Lung Cancer
Register for Updates
Single-incision Versus Retropubic Mid-Urethral Sling (Solyx) for SUI During Minimally Invasive Sacrocolpopexy
NCT04586166
Recruiting
SASS (Single-incision Versus Retropubic Mid-Urethral Sling (Solyx) for SUI During Minimally Invasive Sacrocolpopexy) will be a multicenter, prospective, randomized, single-blind non-inferiority trial.
Gender:
FEMALE
Ages:
21 years and above
Trial Updated:
04/24/2025
Locations: Wake Forest Baptist Medical Center, Winston-Salem, North Carolina
Conditions: Stress Urinary Incontinence, Pelvic Floor Disorders
Register for Updates
Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia
NCT06953869
Recruiting
This is a multicenter, double-blind, randomized study to evaluate the efficacy and safety of a daily single oral dose of tasimelteon and matching placebo in male and female pediatric participants with insomnia disorder.
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
04/23/2025
Locations: Vanda Investigational Site, Charlotte, North Carolina
Conditions: Insomnia Disorder
Register for Updates
Seizure Prevention in Traumatic Brain Injury With Levetiracetam and Lacosamide
NCT06866691
Recruiting
The purpose of this study is to assess the incidence of early post-traumatic seizures. The study will also assess the benefit of lacosamide compared to levetiracetam in regards to agitation and behavioral adverse effects in patients with moderate to severe traumatic brain injury requiring seizure prophylaxis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/23/2025
Locations: Wake Forest University Health Sciences, Winston-Salem, North Carolina
Conditions: Traumatic Brain Injury
Register for Updates
A Clinical Study to Evaluate the Safety and Efficacy of the FloStent in Men With Benign Prostatic Hyperplasia Symptoms
NCT06849258
Recruiting
The goal of this study is to determine the safety and effectiveness of the FloStent, a medical device used to treat men with symptoms of Benign Prostatic Hyperplasia, compared to sham (procedure without deployment of the FloStent). All participants will undergo a flexible cystoscopy and those randomized to the treatment arm will receive the FloStent, while those randomized to the sham arm will not receive the FloStent.
Gender:
MALE
Ages:
45 years and above
Trial Updated:
04/23/2025
Locations: Associated Urologists of North Carolina, Raleigh, North Carolina
Conditions: Benign Prostatic Hyperplasia
Register for Updates
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
NCT06329401
Recruiting
A randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of inhaled pirfenidone (AP01) versus placebo on top of standard of care in participants with PPF over 52 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/23/2025
Locations: Duke University, Durham, North Carolina
Conditions: Progressive Pulmonary Fibrosis
Register for Updates
Topical Treatment for Atopic Dermatitis
NCT06244212
Recruiting
Medication adherence is a poorly studied phenomenon that challenges both patients and physicians. 50% of individuals with chronic disease are not adherent to their medication regimen. Within the United States, non-adherence to medical treatment leads to approximately $100 billion in hospital admission costs. While the issue of adherence is not limited to any particular field of medicine, non-adherence occurs in approximately one-third to one-half of dermatological patients. Non-adherence is of i... Read More
Gender:
ALL
Ages:
9 years and above
Trial Updated:
04/23/2025
Locations: Wake Forest University Health Sciences, Winston-Salem, North Carolina
Conditions: Atopic Dermatitis
Register for Updates
LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer
NCT05900986
Recruiting
The aim of this Phase 1b/2 study is to investigate the safety, efficacy, and pharmacokinetics (PK) of a single dose of LS301-IT, a novel fluorescence imaging agent developed by Integro Theranostics (IT), administered by intravenous (IV) injection in female patients undergoing partial mastectomy for DCIS (whether or not undergoing planned SLNB) or Stage I-II primary invasive breast cancer undergoing SLNB. Safety is the primary objective of this study, followed by efficacy that will be assessed fr... Read More
Gender:
FEMALE
Ages:
Between 18 years and 80 years
Trial Updated:
04/23/2025
Locations: Integro Theranostics Clinical Research Site #8, Winston-Salem, North Carolina
Conditions: Breast Cancer, DCIS, Invasive Duct Carcinoma of Breast
Register for Updates
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT05650632
Recruiting
Multiple Myeloma (MM) is a cancer of the blood's plasma cells ( blood cell). The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed) or may not get better (refractory) with treatment. This is a study to determine adverse events and change in disease symptoms of ABBV-383 in adult participants with relapsed/refractory... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/23/2025
Locations: University of North Carolina /ID# 251203, Chapel Hill, North Carolina
Conditions: Multiple Myeloma
Register for Updates